China NT Pharma Group Co Ltd
China NT Pharma Group Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.
Business. China NT Pharma Group Co Ltd (1011.HK) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
China NT Pharma Group Co Ltd (1011.HK) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
China NT Pharma Group Co Ltd has a market capitalization of 569,398,616.4 CNY, with a market price of 0.6 CNY per share. The company has 948,997,694 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company reported a last actual EPS of 0.74 CNY and a last actual revenue of 915,119,000 CNY. These figures suggest a need for further analysis against industry benchmarks to assess profitability and returns. The company's performance relative to the preferred metrics in the pharmaceutical industry, such as ROIC and EBITDA margins, is not currently available for comparison.
The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdown, it is difficult to assess the diversification of its revenue streams or potential exposure to regional economic fluctuations.
The company's growth trajectory is not clearly defined in the available data. No specific numeric deltas or revenue history are provided to indicate the direction of growth for the current or next fiscal year.
The risk assessment indicates low dilution potential, but liquidity risk remains unassessed due to the lack of balance-sheet inputs and no going-concern language in source documents. The absence of detailed risk factors and dilution potential analysis suggests a need for further scrutiny of the company's financial health and strategic direction.
Recent events, such as filings and transcripts, are not detailed in the available data. The company's recent performance and strategic initiatives are not explicitly outlined, which limits the ability to assess its current market position and future prospects.
- The company has a market capitalization of 569,398,616.4 CNY with a market price of 0.6 CNY per share.
- The company reported a last actual EPS of 0.74 CNY and a last actual revenue of 915,119,000 CNY.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- The company's revenue concentration and geographic exposure are not disclosed in the available data.
- The company's growth trajectory is not clearly defined in the available data.
- The risk assessment indicates low dilution potential, but liquidity risk remains unassessed.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥24.2M, −36,4% YoY; Operating income +107,2% YoY.
- ▍Revenue ¥24.2M, −36,4% YoY
- ▍Operating income +107,2% YoY
- ▍Net income +51,2% YoY
- ▍Net margin -107.8%
Revenue ¥38.0M, +415,3% YoY; Operating income −382,0% YoY.
- ▍Revenue ¥38.0M, +415,3% YoY
- ▍Operating income −382,0% YoY
- ▍Net income +62,8% YoY
- ▍Free cash flow −22,9% YoY
- ▍Net margin -140.6%
Revenue ¥226.7M; Operating income -¥60.0M.
- ▍Revenue ¥226.7M
- ▍Operating income -¥60.0M
- ▍Net margin -66.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- China NT Pharma Group Co Ltd Market data — financials · 2026-05-26
- China NT Pharma Group Co Ltd Market data — analyst estimates · 2026-05-26